The American Institute of Biological Sciences (AIBS) is pleased to support the nomination of Dr. Eric Lander—a geneticist, molecular biologist, and mathematician—as Director of the White House Office of Science and Technology Policy (OSTP) and presidential science advisor.

The Public Policy Report has been released. The report provides analysis and communication on important issues in the scientific community.

President-elect Joe Biden has announced that he will nominate Dr. Eric Lander—a geneticist, molecular biologist, and mathematician—to serve as the Director of the White House Office of Science and Technology Policy (OSTP) and his science adviser.

The Biden-Harris transition team have announced the names of several members of their science team.

The Environmental Protection Agency (EPA) has finalized its data transparency rule to limit the use of certain scientific studies in crafting regulations.

Join the American Institute of Biological Sciences on April 19-23, 2021 for our Virtual Advocacy Event.

On behalf of the scientific, medical, and patient communities dedicated to advancing medical knowledge and improving human health, we congratulate you on your election and urge you, upon taking office, to swiftly rescind the human fetal tissue (HFT) research restrictions and policy changes that the Department of Health and Human Services made in 2019.

The Public Policy Report has been released. The report provides analysis and communication on important issues in the scientific community.

On December 21, 2020, both chambers of Congress passed a $900 billion coronavirus stimulus package along with the fiscal year (FY) 2021 omnibus spending legislation. After demanding changes to relief provisions in the congressionally approved legislation for a week, President Trump capitulated and signed the stimulus-spending bill into law on December 27, 2020, just prior to the expiration of the most recent stopgap funding resolution.

The National Academy of Sciences (NAS) has released proceedings from a February 2020 symposium that summarizes discussions among leading business, academic, and government professionals on the future of science policy in the U.S. and whether the modern research architecture needs to be reconfigured to meet 21st century challenges.